The key COVID-19 findings in economics, distilled into a clear, readable brief. The evidence is here whenever you want to go deeper.
INSIDE THIS MONITOR
39cited sources
21available findings
Study findings updated
AI-assisted evidence summary. For general information. These findings are not individual medical advice or a clinician endorsement.
THE SHORT VERSION
What’s worth knowing.
The key findings, what they mean, and the context that matters.
THE HEADLINE TAKEAWAY
Long COVID cohorts had higher annual healthcare costs
Mean annual total healthcare costs for adults with Long COVID versus contemporary controls were £6681.6 vs £2039.9 in Wales and £3378.3 vs £1355.8 in England.
This England-and-Wales analysis used contemporary controls. Design and adjustment details are not available in this summary.
See the evidence
Mean annual total healthcare cost for adults with Long COVID versus contemporary controls
Wales: £6681.6 vs £2039.9 (3.27-fold); England: £3378.3 vs £1355.8 (2.49-fold)
Dashtban, Ashkan et al.. Healthcare utilisation and cost among individuals with Long COVID in England and Wales: potential value of specialised post-COVID services.. Journal of the Royal Society of Medicine. 2026.
Post-discharge costs exceeded pre-admission costs after COVID-19 hospitalization
Mean all-cause healthcare costs were +$13,808 per patient in the six months after discharge versus the six months before admission. Claims and inpatient days also rose.
Retrospective US claims analysis of Medicare fee-for-service beneficiaries aged ≥65 hospitalized with COVID-19. Index hospitalization costs were excluded; the comparator was the pre-admission period.
See the evidence
Mean all-cause healthcare cost change in the six months after discharge versus the six months before admission among Medicare fee-for-service beneficiaries aged ≥65 hospitalized with COVID-19; index hospitalization costs were excluded.
+$13,808 per patient; p<0.001
Yehoshua, Alon et al.. Costs and healthcare resource utilization after COVID-19 hospitalization among US Medicare patients: a retrospective claims analysis.. Journal of medical economics. 2026.
Change in mean healthcare claims during the six-month post-discharge period versus the six-month pre-admission period among Medicare fee-for-service beneficiaries hospitalized with COVID-19.
+6.1 healthcare claims per patient; p<0.001
Yehoshua, Alon et al.. Costs and healthcare resource utilization after COVID-19 hospitalization among US Medicare patients: a retrospective claims analysis.. Journal of medical economics. 2026.
Change in mean inpatient length of stay during the six-month post-discharge period versus the six-month pre-admission period.
+3.6 inpatient days; p<0.001
Yehoshua, Alon et al.. Costs and healthcare resource utilization after COVID-19 hospitalization among US Medicare patients: a retrospective claims analysis.. Journal of medical economics. 2026.
Financial hardship was higher with activity-limiting Long COVID
27 percentage points higher
Compared with never-infected US adults, financial hardship was 27 percentage points higher with severe activity limitations and 9 percentage points higher with mild limitations.
National study of US adults. These are separate comparisons with never-infected adults, not a direct severe-versus-mild comparison; design and timeframe are unavailable.
See the evidence
Financial hardship for adults with long COVID and severe activity limitations compared to never-infected adults
27 percentage points higher
Das, Vivekananda. Trends in Financial Hardship by COVID-19 Infection History, Long COVID Status, and Day-to-Day Activity Limitations: A National Study of US Adults.. Family & community health. 2024.
Financial hardship for adults with long COVID and mild activity limitations compared to never-infected adults
9 percentage points higher
Das, Vivekananda. Trends in Financial Hardship by COVID-19 Infection History, Long COVID Status, and Day-to-Day Activity Limitations: A National Study of US Adults.. Family & community health. 2024.
Treatment receipt was 31.0% in an eligible high-risk cohort
31.0% (13,499 patients)
Among the study-defined commercially insured population eligible for oral antivirals and at high risk, 31.0% (13,499 patients) received COVID-19 treatment. In the high-risk cohort, ward admission was 9.8%, with $14,715 mean total cost per patient overall.
Retrospective US database analysis. Treatment type was not specified in the finding, and no treated-versus-untreated cost or outcome comparison is available.
See the evidence
Receipt of COVID-19 treatment among the study-defined commercially insured, oral-antiviral-eligible population at high risk of severe disease.
31.0% (13,499 patients)
Mugwagwa, Tendai et al.. Real-world healthcare resource utilization and cost burden of COVID-19 in commercially insured adults at high-risk of severe disease in the US: a retrospective database analysis.. Journal of medical economics. 2026.
All-cause general-ward admission and reported per-patient costs among commercially insured adults at high risk of severe COVID-19.
9.8%; mean total cost $14,715 per patient overall ($10,833 acute; $14,403 post-acute)
Mugwagwa, Tendai et al.. Real-world healthcare resource utilization and cost burden of COVID-19 in commercially insured adults at high-risk of severe disease in the US: a retrospective database analysis.. Journal of medical economics. 2026.
All-cause ICU admission and reported per-patient costs in the high-risk commercially insured cohort.
1.3%; mean total cost $75,371 per patient overall ($62,882 acute; $71,666 post-acute)
Mugwagwa, Tendai et al.. Real-world healthcare resource utilization and cost burden of COVID-19 in commercially insured adults at high-risk of severe disease in the US: a retrospective database analysis.. Journal of medical economics. 2026.
Wastewater surveillance economics hinged on model assumptions
An Ontario health-system model found year-round wastewater surveillance cost-effective at $50,000 CAD per quality-adjusted life-year with Omicron/BA.1-like detection at least 3 days earlier; at least 10 days earlier was cost-saving. For XBB-like outbreaks, at least 6 per decade was cost-effective.
The $15 million CAD/year program was maintained over 10 years; for an Omicron/BA.1-like outbreak, benefits accrued only in the outbreak year. The reference strategy is not identified.
See the evidence
Modeled Ontario health-system analysis of year-round WWS maintained over 10 years for an Omicron/BA.1-like outbreak, assuming benefits accrue only in the outbreak year.
$15 million CAD/year; cost-effective at $50,000 CAD/QALY with at least 3 days earlier detection
Sahakyan, Yeva et al.. Economic evaluation of wastewater surveillance in Ontario, Canada, using COVID-19 as a case study.. Canada communicable disease report = Releve des maladies transmissibles au Canada. 2026.
Modeled Ontario health-system analysis of a $15 million CAD/year WWS program maintained over 10 years for an Omicron/BA.1-like outbreak.
Cost-saving with at least 10 days earlier detection
Sahakyan, Yeva et al.. Economic evaluation of wastewater surveillance in Ontario, Canada, using COVID-19 as a case study.. Canada communicable disease report = Releve des maladies transmissibles au Canada. 2026.
Modeled scenario involving less severe, lower-transmission XBB-like outbreaks.
Cost-effective with at least 6 outbreaks per decade
Sahakyan, Yeva et al.. Economic evaluation of wastewater surveillance in Ontario, Canada, using COVID-19 as a case study.. Canada communicable disease report = Releve des maladies transmissibles au Canada. 2026.
Treatment uptake and admission costs in high-risk adults
31.0% (13,499 patients)
Among the study-defined oral-antiviral-eligible population, 31.0% (13,499 patients) received COVID-19 treatment. In the high-risk cohort, ward admission was 9.8% with $14,715 mean total cost per patient overall; intensive-care admission was 1.3% with $75,371.
Retrospective US database analysis of commercially insured adults at high risk of severe COVID-19. Treatment type and treated-versus-untreated cost or outcome comparisons are unavailable.
Study details & original results
Mugwagwa, Tendai et al.. Real-world healthcare resource utilization and cost burden of COVID-19 in commercially insured adults at high-risk of severe disease in the US: a retrospective database analysis.. Journal of medical economics. 2026.
Receipt of COVID-19 treatment among the study-defined commercially insured, oral-antiviral-eligible population at high risk of severe disease.
31.0% (13,499 patients)
All-cause general-ward admission and reported per-patient costs among commercially insured adults at high risk of severe COVID-19.
9.8%; mean total cost $14,715 per patient overall ($10,833 acute; $14,403 post-acute)
All-cause ICU admission and reported per-patient costs in the high-risk commercially insured cohort.
1.3%; mean total cost $75,371 per patient overall ($62,882 acute; $71,666 post-acute)
Post-discharge healthcare use exceeded pre-admission levels
Mean all-cause healthcare costs were +$13,808 per patient in the six months after discharge versus the six months before admission. Mean claims increased by 6.1 per patient and mean inpatient length of stay by 3.6 days.
Retrospective US claims analysis of Medicare fee-for-service beneficiaries aged ≥65 hospitalized with COVID-19. Index hospitalization costs were excluded.
Study details & original results
Yehoshua, Alon et al.. Costs and healthcare resource utilization after COVID-19 hospitalization among US Medicare patients: a retrospective claims analysis.. Journal of medical economics. 2026.
Mean all-cause healthcare cost change in the six months after discharge versus the six months before admission among Medicare fee-for-service beneficiaries aged ≥65 hospitalized with COVID-19; index hospitalization costs were excluded.
+$13,808 per patient; p<0.001
Change in mean healthcare claims during the six-month post-discharge period versus the six-month pre-admission period among Medicare fee-for-service beneficiaries hospitalized with COVID-19.
+6.1 healthcare claims per patient; p<0.001
Change in mean inpatient length of stay during the six-month post-discharge period versus the six-month pre-admission period.
Wastewater surveillance economics depended on timing and outbreaks
An Ontario health-system model found year-round wastewater surveillance cost-effective at $50,000 CAD per quality-adjusted life-year with Omicron/BA.1-like detection at least 3 days earlier; at least 10 days earlier was cost-saving. For XBB-like outbreaks, at least 6 per decade was cost-effective.
The $15 million CAD/year program was maintained over 10 years; for an Omicron/BA.1-like outbreak, benefits accrued only in the outbreak year. The reference strategy is not identified.
Study details & original results
Sahakyan, Yeva et al.. Economic evaluation of wastewater surveillance in Ontario, Canada, using COVID-19 as a case study.. Canada communicable disease report = Releve des maladies transmissibles au Canada. 2026.
Modeled Ontario health-system analysis of year-round WWS maintained over 10 years for an Omicron/BA.1-like outbreak, assuming benefits accrue only in the outbreak year.
$15 million CAD/year; cost-effective at $50,000 CAD/QALY with at least 3 days earlier detection
Modeled Ontario health-system analysis of a $15 million CAD/year WWS program maintained over 10 years for an Omicron/BA.1-like outbreak.
Cost-saving with at least 10 days earlier detection
Modeled scenario involving less severe, lower-transmission XBB-like outbreaks.
Cost-effective with at least 6 outbreaks per decade
Long COVID costs were higher than controls in both countries
Mean annual total healthcare costs for adults with Long COVID versus contemporary controls were £6681.6 vs £2039.9 in Wales and £3378.3 vs £1355.8 in England.
This England-and-Wales analysis used contemporary controls. Design, cohort-selection and adjustment details are not available in this summary.
Study details & original results
Dashtban, Ashkan et al.. Healthcare utilisation and cost among individuals with Long COVID in England and Wales: potential value of specialised post-COVID services.. Journal of the Royal Society of Medicine. 2026.
Mean annual total healthcare cost for adults with Long COVID versus contemporary controls
Wales: £6681.6 vs £2039.9 (3.27-fold); England: £3378.3 vs £1355.8 (2.49-fold)
Dates show when findings were added here, not when papers were published. Study populations and comparisons differ.
WHEN YOU WANT TO GO DEEPERSee all 21 findingsOriginal results, comparisons and study details.
6 of 6 source groupsFindings stay together with their study.
SOURCE 393 findings
Mugwagwa, Tendai et al.. Real-world healthcare resource utilization and cost burden of COVID-19 in commercially insured adults at high-risk of severe disease in the US: a retrospective database analysis.. Journal of medical economics. 2026.
Yehoshua, Alon et al.. Costs and healthcare resource utilization after COVID-19 hospitalization among US Medicare patients: a retrospective claims analysis.. Journal of medical economics. 2026.
Mean all-cause healthcare cost change in the six months after discharge versus the six months before admission among Medicare fee-for-service beneficiaries aged ≥65 hospitalized with COVID-19; index hospitalization costs were excluded.
Change in mean healthcare claims during the six-month post-discharge period versus the six-month pre-admission period among Medicare fee-for-service beneficiaries hospitalized with COVID-19.
Added
+6.1 healthcare claims per patient; p<0.001Source [38]
SOURCE 373 findings
Sahakyan, Yeva et al.. Economic evaluation of wastewater surveillance in Ontario, Canada, using COVID-19 as a case study.. Canada communicable disease report = Releve des maladies transmissibles au Canada. 2026.
Modeled Ontario health-system analysis of year-round WWS maintained over 10 years for an Omicron/BA.1-like outbreak, assuming benefits accrue only in the outbreak year.
Added
$15 million CAD/year; cost-effective at $50,000 CAD/QALY with at least 3 days earlier detectionSource [37]
Modeled Ontario health-system analysis of a $15 million CAD/year WWS program maintained over 10 years for an Omicron/BA.1-like outbreak.
Added
Cost-saving with at least 10 days earlier detectionSource [37]
All 3 findings from this source
Modeled scenario involving less severe, lower-transmission XBB-like outbreaks.
Added
Cost-effective with at least 6 outbreaks per decadeSource [37]
SOURCE 364 findings
Dashtban, Ashkan et al.. Healthcare utilisation and cost among individuals with Long COVID in England and Wales: potential value of specialised post-COVID services.. Journal of the Royal Society of Medicine. 2026.
2-4MWorkers out of labor force due to Long COVIDSource [3]
SOURCE 356 findings
Das, Vivekananda. Trends in Financial Hardship by COVID-19 Infection History, Long COVID Status, and Day-to-Day Activity Limitations: A National Study of US Adults.. Family & community health. 2024.
Chen C, Haupert SR, Zimmermann L, et al. Global Prevalence of Post-Coronavirus Disease 2019 (COVID-19) Condition or Long COVID: A Meta-Analysis and Systematic Review. J Infect Dis. 2022;226(9):1593-1607.
Bull-Otterson L, Baca S, Saydah S, et al. Post-COVID Conditions Among Adult COVID-19 Survivors Aged 18-64 and >=65 Years - United States, March 2020-November 2021. MMWR. 2022;71(21):713-717.
Original source link unavailable
[12]
Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nature Reviews Microbiology. 2023;21(3):133-146.
Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and psychiatric outcomes in 236,379 survivors of COVID-19. Lancet Psychiatry. 2021;8(5):416-427.
Ballering AV, van Zon SKR, Olde Hartman TC, Rosmalen JGM. Persistence of somatic symptoms after COVID-19 in the Netherlands. Lancet. 2022;400(10350):452-461.
Meltzer MI, et al. Modeling COVID-19 control measures and their effects. CDC MMWR. 2020.
Original source link unavailable
[35]
Das, Vivekananda. Trends in Financial Hardship by COVID-19 Infection History, Long COVID Status, and Day-to-Day Activity Limitations: A National Study of US Adults.. Family & community health. 2024.
Dashtban, Ashkan et al.. Healthcare utilisation and cost among individuals with Long COVID in England and Wales: potential value of specialised post-COVID services.. Journal of the Royal Society of Medicine. 2026.
Sahakyan, Yeva et al.. Economic evaluation of wastewater surveillance in Ontario, Canada, using COVID-19 as a case study.. Canada communicable disease report = Releve des maladies transmissibles au Canada. 2026.
Yehoshua, Alon et al.. Costs and healthcare resource utilization after COVID-19 hospitalization among US Medicare patients: a retrospective claims analysis.. Journal of medical economics. 2026.
Mugwagwa, Tendai et al.. Real-world healthcare resource utilization and cost burden of COVID-19 in commercially insured adults at high-risk of severe disease in the US: a retrospective database analysis.. Journal of medical economics. 2026.
This is an AI-assisted evidence summary, not a clinician endorsement. Read each original paper for its complete methods, population and limitations. Different studies can ask different questions and report different kinds of results.
Dates marked “added” describe when a finding entered this monitor, not when the study was published or clinically reviewed. Personal health and treatment decisions belong in a conversation with a qualified clinician.